Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed adenocarcinoma of the breast by fine needle aspirate, biopsy (tru-cut, core, stereotactic), lumpectomy, or modified radical mastectomy
• •* Stage I-III (any T, any N, M0)
• •* Stage IV due solely to supraclavicular node involvement allowed
• •Plan to use adjuvant chemotherapy\* with or without adjuvant endocrine therapy\*
• •* Subsequent adjuvant hormonal therapy with an aromatase inhibitor allowed in women rendered postmenopausal by adjuvant chemotherapy NOTE: \*Must be specified prior to study entry
• •Hormone receptor status:
• •* Not specified
• •PATIENT CHARACTERISTICS:
• •Age:
• •40 and over
• •Sex:
• •Female
• •Menopausal status:
• •See Disease Characteristics
• •Premenopausal, defined as actively menstruating or last menstrual period occurred within 6 months prior to study entry
• •* Prior hysterectomy without bilateral oophorectomy and estradiol and follicle-stimulating hormone within premenopausal range prior to the initiation of chemotherapy allowed
• •Performance status:
• •Not specified
• •Life expectancy:
• •Not specified
• •Hematopoietic:
• •Not specified
• •Hepatic:
• •Not specified
• •Renal:
• •Not specified
• •Other:
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •Not specified
• •Chemotherapy:
• •See Disease Characteristics
• •No more than 3 months since prior adjuvant chemotherapy
• •Endocrine therapy:
• •See Disease Characteristics
• •Radiotherapy:
• •Not specified
• •Surgery:
• •See Disease Characteristics
• •See Menopausal status
• •Other:
• •No other concurrent bisphosphonates
• •No concurrent digoxin
• •No concurrent tetracycline
• •Concurrent neoadjuvant therapy allowed
• •Concurrent enrollment on therapeutic adjuvant clinical trials allowed provided the therapeutic trial does not preclude participation in this trial